Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Cooley

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2010
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasErica D Warlick, Marcie Tomblyn, Qing Cao, et al.
Nature Medicine|February 1, 2022
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trialJeffrey S Miller, Zachary B Davis, Erika Helgeson, et al.
Science Translational Medicine|November 27, 2015
Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease preventionScott N Furlan, Benjamin Watkins, Victor Tkachev, et al.
Blood|November 19, 2021
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapyMelissa M Berrien-Elliott, Michelle Becker-Hapak, Amanda F Cashen, et al.
Med (New York, N.Y.)|May 12, 2023
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumorsJohn Goulding, Wen-I Yeh, Bryan Hancock, et al.
Blood Advances|February 25, 2020
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantationDaniel Weisdorf, Sarah Cooley, Tao Wang, et al.
Blood|February 22, 2018
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Sarah Cooley, Melissa M Berrien-Elliott, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 5, 2010
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasErica D Warlick, Marcie Tomblyn, Qing Cao, et al.
Nature Medicine|February 1, 2022
Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trialJeffrey S Miller, Zachary B Davis, Erika Helgeson, et al.
Science Translational Medicine|November 27, 2015
Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease preventionScott N Furlan, Benjamin Watkins, Victor Tkachev, et al.
Blood|November 19, 2021
Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapyMelissa M Berrien-Elliott, Michelle Becker-Hapak, Amanda F Cashen, et al.
Med (New York, N.Y.)|May 12, 2023
A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumorsJohn Goulding, Wen-I Yeh, Bryan Hancock, et al.
Blood Advances|February 25, 2020
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantationDaniel Weisdorf, Sarah Cooley, Tao Wang, et al.
Blood|February 22, 2018
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantationRizwan Romee, Sarah Cooley, Melissa M Berrien-Elliott, et al.
Pageof 9